• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文会议>Annual International Conference of the IEEE Engineering in Medicine and Biology Society >Early Detection of Amyloid β Pathology in Alzheimer’s Disease by Molecular MRI*
【24h】

Early Detection of Amyloid β Pathology in Alzheimer’s Disease by Molecular MRI*

机译：分子MRI早期检测阿尔茨海默氏病中淀粉样β病理学*

获取原文
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Alzheimer’s disease (AD) is a degenerative brain disease and the most common cause of dementia. Early stage β-amyloid oligomers (AβOs) and late stage Aβ plaques are the pathological hallmarks of AD brains. AβOs are known to be more neurotoxic and contribute to neuronal damage. Most current approaches are focused on detecting Aβ plaques, which occurs at the late stage of AD, and are limited by poor sensitivity and/or contrast agent toxicity. In previous studies, we developed a new curcumin-conjugated magnetic nanoparticle (Cur-MNPs) to target the Aβ pathologies. In this study, we investigate the in vivo feasibility of this novel Cur-MNPs to detect Aβ pathologies at the early and late stages of AD in transgenic AD mice and perform immunohistochemical examinations to validate the specific targeting of various form of Aβ pathologies.
机译：阿尔茨海默氏病（AD）是一种退化性脑病，也是痴呆症的最常见原因。早期β-淀粉样蛋白低聚物（AβOs）和晚期Aβ斑块是AD脑的病理标志。已知AβO具有更高的神经毒性，并有助于神经元的损害。当前大多数方法都集中于检测Aβ斑块，该斑块发生在AD晚期，并受到灵敏度和/或造影剂毒性差的限制。在以前的研究中，我们开发了一种新的姜黄素共轭磁性纳米颗粒（Cur-MNPs）来靶向Aβ病理学。在这项研究中，我们调查了这种新型Cur-MNP在体内检测转基因AD小鼠AD早期和晚期Aβ病理的体内可行性，并进行免疫组织化学检查以验证各种形式Aβ病理的特异性靶向。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号